Analysis of Influence of Bicyclol Tablets on Renal Function Based on Real World

Abstract

Abstract: Objective To understand the effect of bicyclol tablets on serum creatinine and blood urea nitrogen in clinical practice through descriptively analyzing real world use data of bicyclol tablets, which used serum creatinine and blood urea nitrogen, the conventional test of renal function test, as final indicators, so as to provide evidence for further discussion on the safety to kidney. Methods The clinical use information of the bicyclol tablets from 18 hospitals in China was selected. The abnormal rates of serum creatinine and blood urea nitrogen in patients with or without the bicyclol tablets were analyzed by Chi-square test respectively. Results The abnormal rates of serum creatinine and blood urea nitrogen in patients with the bicyclol tablets were significantly lower than that without use (χ2=10.784 6, P=0.001 0; χ2=11.442 1, P=0.000 7). Conclusion In the real world, the bicyclol tablets have no significant damages to kidney.

Key words: bicyclol, renal function, real world, safety

CLC Number:

R994.11

HOU Dao-rui, LI Yuan, XIE Yan-ming,* ZHAO Wei, ZHUANG Yan. Analysis of Influence of Bicyclol Tablets on Renal Function Based on Real World[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 291-294.

References

[1] 高欣涛, 黄月莹, 刘弘,等. 双环醇严重不良反应1例报道及联合用药分析[J]. 中国药师, 2014, 17(6):982-983.
[2] 尹航. 双环醇片(百赛诺)Ⅳ期临床试验圆满完成临床应用专家意见取得共识[J]. 中国处方药, 2004, (9):25-27.
[3] 刘颖, 樊蓉, 陈简, 等. 慢性乙型肝炎病毒感染相关肝硬化患者的肾功能及危险因素分析[J]. 南方医科大学学报, 2014, (4):472-476.
[4] 张友文, 魏怀玲, 鲍秀琦, 等. 双环醇对顺铂联合吉西他滨致荷瘤小鼠肝肾损伤的保护作用[J]. 中国药物警戒, 2014, 11(5):257-260.
[5] Cui J, Li Z, Qian L B, et al. Reducing the oxidative stress mediates the cardioprotection of bicyclol against ischemia-reperfusion injury in rats[J]. Journal of Zhejiang University-Science B(Biomedicine & Biotechnology), 2013, 14(6):487-495.
[6] Luo Y, Zhang B, Xu D Q, et al. Protective effect of bicyclol on lipopolysaccharide-induced acute lung injury in mice.[J]. Pulmonary Pharmacology & Therapeutics, 2011, 24(2):240-246.
[7] 刘艳红, 韩子明. 双环醇对单侧输尿管梗阻大鼠肾间质纤维化的影响及作用机制[J]. 中华肾脏病杂志, 2010, 26(12):932-933.
[8] 张健. 双环醇对实验性脑梗死大鼠抗炎症损伤机制的研究[D]. 河北医科大学, 2013.
[9] 孟晓华, 董科, 徐湜潺, 等. 双环醇对肾间质纤维化大鼠的干预作用[J]. 中国医药导报, 2014, (29):15-18.
[10] 赵冬梅, 孙韬, 李燕. 双环醇对大鼠肾脏缺血-再灌注损伤的保护作用[J]. 药学学报, 2002, 37(6):412-414.
[11] 胡小鹏, 尹航, 王玮, 等. 双环醇片治疗肾移植术后药物性肝损伤的疗效观察[J]. 胃肠病学和肝病学杂志, 2012, 21(4):342-344.
[12] 汪翊, 夏梦迪, 谢席胜,等. 双环醇治疗肾病综合征合并药物肝损害的疗效与安全性评价[J]. 西部医学, 2014, 26(11):1469-1470.
[13] 杨再娇, 沈华良, 王巧珍, 等. 双环醇治疗低复制型乙肝相关性肾炎临床研究[J]. 海峡药学, 2011, 23(7):144-145.
[14] Xie Y M, Tian F. Regulations and guidelines shoule be strenghened urgently for re-evaluation on post-marketing medicine in china[J].Chin J Integr Med，2013, 19(7):483-487.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[3]	BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
[4]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[5]	XIONG Weiyi, REN Jingtian. Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
[6]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[7]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[8]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[9]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[10]	SHI Bowen, LI Lixun, XIE Yanming, WANG Zhifei, WANG Qi. Clinical characteristics of Xiyanping injection in 3846 patients with bacterial intestinal infection in the real world [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1017-1021.
[11]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[12]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
[13]	YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo. Risks of safety Qingkailing oral preparation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
[14]	LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli. Adverse reactions in patients with COVID-19 after using tocilizumab [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
[15]	LI Yamei, SHUI Rong. Research progress in tofacitinib for juvenile idiopathic arthritis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 956-960.